Adverse events following immunization (AEFIs) with anti-meningococcus type B vaccine (4CMenB): Data of post-marketing active surveillance program. Apulia Region (Italy), 2019

Adverse events following immunization (AEFIs) with anti-meningococcus type B vaccine (4CMenB): Data of post-marketing active surveillance program. Apulia Region (Italy), 2019–2023

Published:2023-11 Issue:48 Volume:41 Page:7096-7102
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

Stefanizzi Pasquale,Di Lorenzo Antonio,Martinelli Andrea,Moscara Lorenza,Stella Paolo,Ancona Domenica,Tafuri Silvio

Publisher

Elsevier BV

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine

Reference44 articles.

1. European Medicine Agency. Bexsero: EPAR - product information. Amsterdam. 28/01/2013. Last updated: 12/10/2022.

2. European Medicine Agency. Trumenba: EPAR - product information. Amsterdam. 06/06/2017. Last updated: 14/11/2022.

3. Safety profile of MenB-FHBp vaccine among adolescents: data from surveillance of Adverse Events Following Immunization in Puglia (Italy), 2018–2020;Stefanizzi;Hum Vaccin Immunother,2022

4. Italian Republic. Ministry of Health. Permanent Conference for the relationships among the State, the Regions and Trento and Bolzano’s autonomous provinces. Intesa, ai sensi dell’articolo 8, comma 6, della legge 5 giugno 2003, n. 131, tra il Governo, le regioni e le province autonome di Trento e Bolzano sul documento recante “Piano nazionale prevenzione vaccinale 2017-2019”. General Series’ Official Gazette n. 41, 18 February 2017.

5. Preventing infections in children and adults with asplenia;Lee;Hematology Am Soc Hematol Educ Prog,2020

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Policies for the immunization against serogroup B meningococcus for adolescents immunized during the first two years of life: A mini review;Human Vaccines & Immunotherapeutics;2024-09-12

2. Adverse effects of COVID-19 vaccines in the Moroccan adults and children during the pandemic;Clinical Epidemiology and Global Health;2024-07

3. Safety profile of recombinant adjuvanted anti-herpes zoster vaccine (RZV) in high-risk groups: Data from active surveillance program. Puglia (Italy), 2021–23;Vaccine;2024-04

4. Meningococcal group B vaccine increases risk of fever in infants;Reactions Weekly;2023-11-11